AGN 194310 - CAS 229961-45-9
Catalog number: 229961-45-9
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C28H24O2S
Molecular Weight:
424.55
COA:
Inquire
Targets:
RAR/RXR
Description:
A high affinity pan-RAR antagonist (AGN194310, K(d) for binding to RARs = 2-5 nM) inhibited colony formation (by 50%) by all three lines at 16-34 nM, and led to a transient accumulation of flask-cultured cells in G1 followed by apoptosis. AGN194310 is 12-22 fold more potent than all-trans retinoic acid (ATRA) against cell lines and also more potent in inhibiting the growth of primary prostate carcinoma cells. The administration of all-trans retinoic acid to VAD mice resulted in a transient reduction in NF-kappaB activity and, conversely, a single dose of the RAR-pan-antagonist, AGN 194310, administered to control mice, led to a marked, transient induction of whole-body luminescence. Mice were treated with AGN194310, a synthetic retinoid that antagonises the physiological function of the three RAR isotypes (alpha, beta, gamma) but does not interact with RXRs. Analyses of the granulocytic lineage using Gr-1, c-Kit and CD11b antibodies, demonstrated that granulocyte numbers were strikingly increased across haemopoietic compartments in all AGN194310-treated mice. A significant increase in the frequency of progenitor cells containing granulocytes was observed in the bone marrow of mice following treatment with AGN194310.
Purity:
>98%
Synonyms:
AGN194310; AGN-194310; VTP194310; VTP 194310; VTP-194310
MSDS:
Inquire
InChIKey:
LHUPKWKWYWOMSK-UHFFFAOYSA-N
InChI:
InChI=1S/C28H24O2S/c1-4-19-7-12-22(13-8-19)25-18-28(2,3)31-26-16-11-21(17-24(25)26)6-5-20-9-14-23(15-10-20)27(29)30/h7-18H,4H2,1-3H3,(H,29,30)
Canonical SMILES:
CCC1=CC=C(C=C1)C2=CC(SC3=C2C=C(C=C3)C#CC4=CC=C(C=C4)C(=O)O)(C)C
1.An antagonist of retinoic acid receptors more effectively inhibits growth of human prostate cancer cells than normal prostate epithelium.
Keedwell RG;Zhao Y;Hammond LA;Wen K;Qin S;Atangan LI;Shurland DL;Wallace DM;Bird R;Reitmair A;Chandraratna RA;Brown G Br J Cancer. 2004 Aug 2;91(3):580-8.
Screening of synthetic retinoids for activity against prostate carcinoma cell lines has identified antagonists of retinoic acid receptors (RARs) as potent growth inhibitors (Hammond et al, 2001, Br J Cancer 85, 453-462). Here we report that 5 days of exposure to a high-affinity pan-RAR antagonist (AGN194310) abolished growth of prostate carcinoma cells from 14 out of 14 patients, with half-maximal inhibition between 200 and 800 nM. It had similar effects (at approximately 250 nM) on the prostate carcinoma lines LNCaP, DU-145 and PC-3. AGN194310 inhibited the growth of normal prostate epithelium cells less potently, by 50% at approximately 1 microM. The growth of tumour cells was also inhibited more than that of normal cells when RARbeta together with RARgamma, but not RARalpha alone, were antagonised. Treatment of LNCaP cells with AGN194310 arrested them in G1 of cell cycle within 12 h, with an accompanying rise in the level of p21(waf1). The cells underwent apoptosis within 3 days, as indicated by mitochondrial depolarisation, Annexin V binding and DNA fragmentation. Apoptosis was caspase-independent: caspases were neither cleaved nor activated, and DNA fragmentation was unaffected by the pan-caspase inhibitor Z-VAD-FMK.
2.Antagonists of retinoic acid receptors (RARs) are potent growth inhibitors of prostate carcinoma cells.
Hammond LA;Van Krinks CH;Durham J;Tomkins SE;Burnett RD;Jones EL;Chandraratna RA;Brown G Br J Cancer. 2001 Aug 3;85(3):453-62.
Novel synthetic antagonists of retinoic acid receptors (RARs) have been developed. To avoid interference by serum retinoids when testing these compounds, we established serum-free grown sub-lines (>3 years) of the prostate carcinoma lines LNCaP, PC3 and DU145. A high affinity pan-RAR antagonist (AGN194310, K(d) for binding to RARs = 2-5 nM) inhibited colony formation (by 50%) by all three lines at 16-34 nM, and led to a transient accumulation of flask-cultured cells in G1 followed by apoptosis. AGN194310 is 12-22 fold more potent than all-trans retinoic acid (ATRA) against cell lines and also more potent in inhibiting the growth of primary prostate carcinoma cells. PC3 and DU145 cells do not express RARbeta, and an antagonist with predominant activity at RARbeta and RARgamma (AGN194431) inhibited colony formation at concentrations (approximately 100 nM) commensurate with a K(d)value of 70 nM at RARgamma. An RARalpha antagonist (AGN194301) was less potent (IC(50) approximately 200 nM), but was more active than specific agonists of RARalpha and of betagamma. A component(s) of serum and of LNCaP-conditioned medium diminishes the activity of antagonists: this factor is not the most likely candidates IGF-1 and EGF.
3.Retinoic acid receptor antagonism in vivo expands the numbers of precursor cells during granulopoiesis.
Walkley CR;Yuan YD;Chandraratna RA;McArthur GA Leukemia. 2002 Sep;16(9):1763-72.
The role/s of retinoids in granulopoiesis has been recognised for many years, being powerful differentiation inducers. The physiological role/s of retinoic acid receptor (RAR)-mediated signalling during adult haemopoiesis has by contrast proved more elusive. The recent generation of highly specific pan-RAR antagonists has now made possible an assessment of the specific physiological role/s of RAR signalling, allowing the separation for the first time of the RAR and RXR pathways. Mice were treated with AGN194310, a synthetic retinoid that antagonises the physiological function of the three RAR isotypes (alpha, beta, gamma) but does not interact with RXRs. Analyses of the granulocytic lineage using Gr-1, c-Kit and CD11b antibodies, demonstrated that granulocyte numbers were strikingly increased across haemopoietic compartments in all AGN194310-treated mice. A significant increase in the frequency of progenitor cells containing granulocytes was observed in the bone marrow of mice following treatment with AGN194310. In contrast we were not able to detect any differences in cell death of either mature granulocytes or granulocytic progenitors from AGN194310-treated mice compared with control animals.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related RAR/RXR Products


CAS 911110-93-5 Adapalene sodium salt

Adapalene sodium salt
(CAS: 911110-93-5)

Adapalene sodium salt, a synthetic retinoid, is a Retinoic acid receptor agonist (RAR). It is a third-generation topical retinoid primarily used in the treatmen...

CAS 196961-43-0 CD 3254

CD 3254
(CAS: 196961-43-0)

CD 3254 is a selective RXRα agonist with no activity at RARα, RARβ or RARγ receptors.

CAS 155877-83-1 LE 135

LE 135
(CAS: 155877-83-1)

LE 135 is a retinoic acid antagonist which shows moderate selectivity for RARβ over RARα. It can inhibit human HL-60 leukemia cell differentiation induced by Am...

CAS 106685-40-9 Adapalene

Adapalene
(CAS: 106685-40-9)

Adapalene is more active than indomethacin, betamethasone valerate, tretinoin, isotretinoin or etretinate in inhibiting lipoxygease activity, but it has little ...

CAS 55079-83-9 Acitretin

Acitretin
(CAS: 55079-83-9)

Acitretin is a second generation retinoid used for psoriasis.

CAS 170355-37-0 CD 2314

CD 2314
(CAS: 170355-37-0)

CD 2314 is a potent and selective RARβ receptor agonist (Kd = 145 and >3760 nM for RARβ and RARα receptors, respectively).

CAS 870773-76-5 AC 261066

AC 261066
(CAS: 870773-76-5)

AC 261066 is a potent RARβ2 agonist (pEC50 = 8.1).

CAS 253310-42-8 BMS 195614

BMS 195614
(CAS: 253310-42-8)

BMS 195614 is a neutral RAR α-selective antagonist (Ki = 2.5 nM) and exhibits no significant effect on nuclear receptor corepressor (NCoR) binding. BMS 195614 m...

Chemical Structure

CAS 229961-45-9 AGN 194310

Quick Inquiry

Verification code

Featured Items